The President made the remarks on Friday, August 27, 2021. He made the announcement after a meeting with BioNTech CEO Uğur Şahin. Organized by the KENUP Foundation.

It was also attended by President Macky Sall of Senegal and President of the Commission of the European Union, EU, Ursula von der Leyen.

President Kagame commends BioNTech for providing technology that will help in Africa's vision as a continent that needs to use it urgently.

The trip to help Africa achieve its goal of launching a vaccine on the continent was also attended by President Macky Sall, who worked to coordinate efforts to speed it up.

President Kagame said: “It is an exciting time. I appreciate the effort we are all putting into this discussion and this is the foundation that should be built on it. ''

He stressed that the steps taken clearly reflect the achievements of the African Union.

“Africa works well when it works together,” President Kagame said. It is important that the program be built at the continental level through the African Union and the African CDC.

“Vaccination in Africa is possible because of the innovations created by BioNTech and its partners and others. "Africa is open to investment and trade is on the way to a sustainable economy."

The Head of State thanked the President of the EU Commission, Ursula von der Leyen and other organizations including the Mastercard Foundation and the International Finance Corporation for their contributions.

So far, the first step will be to start vaccination in Africa and Rwanda, especially after it has been vaccinated. It will be achieved through cooperation including the EU, the European Investment Bank, the European Investment Bank (EIB), the United Nations World Health Organization (WHO) and the Africa CDC.

Rwanda and Senegal are the first countries to be considered for vaccine manufacturing.

BioNTech was involved in the development of the first Covid-19 vaccine in collaboration with Pfizer, the US-based company that specializes in pharmaceuticals; chances are that these vaccines will start to be produced in the country.

A statement from the agency said it believed the construction was based on the implementation of COVID-19 vaccines, which focused on the start of operations in Rwanda and Senegal for malaria and tuberculosis vaccines.

The vaccines that will be used will use a modern method known as mRNA that allows the recipient of his or her body the ability to create immunity made up of antibodies that protect against the virus.

Africa has begun to consider vaccinating itself after the COVID-19 outbreak, based on the fact that it was ignored during the distribution.

Malaria is thought to be one of the most common diseases in Africa, with WHO reporting that in 2019 it accounted for 94% of all reported deaths.

BioNTech had announced plans to enter the African market and vaccinate against malaria in July.

The vaccine is set to begin in African countries as the world sets a 2030 deadline for malaria and tuberculosis.

Since joining the COVID-19 vaccine industry, BioNTech has made huge profits and hopes to generate at least $ 18.7 billion from sales.